Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 28;21:70. doi: 10.1186/s12951-023-01828-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 7 — BEC-EVs and BMSC-EVs treatments antagonized Cav-1-dependent ZO-1 and Claudin-5 endocytosis to decrease BBB permeability. A Representative western blotting of Cav-1 in OGD insulted b. End3 cells and BMV from ischemic cortex; and quantification of Cav-1 expression (n = 3). B Representative western blotting of ZO-1, Claudin-5 and Cav-1 after Cav-1 siRNA transfection in OGD insulted b. End3 cells and quantification of ZO-1, Claudin-5 and Cav-1 expressions (n = 3). C Relative permeability coefficient of OGD insulted b. End3 cells after siRNA/pcDNA 3.1 transfection (n = 4). D Representative western blotting of Cav-1 in subcellular fractions. MF Membrane fraction; CF Cytoplasm fraction; ACF Actin cytoskeleton fraction; Fractions REF. (Calpain I for AF, Calnexin for MF and Vimentin for ACF, respectively) and quantification of Cav-1 expression in subcellular fractions (n = 3). E Representative co-ip results of Cav-1 with ZO-1 and Claudin-5 after Cav-1 pcDNA 3.1 transfection in b. End3 cells, and IgG was served as negative control. IP: Immunoprecipitation; IB: Immunoblotting. F Relative permeability coefficient of OGD insulted b. End3 cells with pcDNA 3.1 transfection after the treatments of EVs from two sources (n = 4). ^***P < 0.001, ^**P < 0.01 vs. Control/SHAM group; ^###P < 0.001, ^#P < 0.05 vs. pMCAo/OGD group; ^†††P < 0.0001, vs. pMCAo + BEC-EVs. ^§§§P < 0.001, ^§§P < 0.01 vs. Ctrl-siRNA/pcDNA 3.1 group. ^‡‡‡P < 0.001 vs. OGD + pcDNA 3.1 + BEC-EVs group; ^¶¶¶P < 0.001 vs. OGD + pcDNA 3.1 + BMSC-EVs group